
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is an innovative company with a diverse product portfolio, strong international presence, and a focus on less invasive medical devices. The proposed update to society guidelines on transcatheter left atrial appendage occlusion is a positive development, highlighting the potential for growth in this area. Additionally, despite recent challenges, the company's management remains confident in its overall growth prospects and has a solid plan for recovering from the recent cybersecurity incident. Potential upside drivers include strong performance in electrophysiology and WATCHMAN, as well as potential growth from recent acquisitions and margin expansion.
Bears say
Boston Scientific is facing several challenges, such as slowing sales of its Watchman device due to mixed clinical evidence, share losses in the US EP market, and potential regulatory hurdles. The company has also faced economic uncertainties and pricing pressures in developed and emerging markets, which could impact its bottom line. Furthermore, the company's recent guidance cuts indicate a challenging near-term outlook, particularly for its Watchman and EP businesses.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares